Although he had been offered dulaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), he declined its use based on concerns from his home care nurse about a potential risk of thyroid cancer. This evidence concerns the gene GLP1R and thyroid gland carcinoma.